Aurobindo Pharma profit and loss

Latest FY26

Revenue: ₹33,653cr+6.1% on FY25
EBITDA: ₹6,846cr+4.0% on FY25
Net profit: ₹3,503cr+0.6% on FY25
EPS: ₹60.34+0.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	34,935	33,653	31,724	29,002	24,855	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	690	492	622	557	291
	35,625	34,145	32,346	29,559	25,146
	10,664	10,305	10,737	10,776	9,653
	3,602	3,478	2,887	2,773	2,050
	−390	−295	−598	−946	−410
	5,442	5,190	4,476	3,923	3,522
	388	384	457	290	140
	1,859	1,778	1,649	1,522	1,245
	8,532	8,129	7,639	6,633	6,321
	30,097	28,970	27,248	24,970	22,522
	7,085	6,846	6,583	5,843	3,719
	5,226	5,068	4,933	4,321	2,474
Profit
	5,528	5,176	5,098	4,589	2,624
	−106	−65.3	0.0	−192	0.0
	5,422	5,110	5,098	4,397	2,624
	1,855	1,736	1,700	1,778	1,071
	−146	−127	−117	−567	−387
	1,709	1,609	1,583	1,211	685
	−1.9	1.5	−31.7	−17.2	−11.7
	3,711	3,503	3,484	3,169	1,928
	3,713	3,501	3,515	3,186	1,939
	1,512	1,965	304	99.2	736
	5,223	5,468	3,787	3,268	2,663
	3,713	3,505	3,486	3,173	1,928
	−1.8	−1.8	−2.3	−4.0	0.2
Per share
	₹64.00	₹60.34	₹59.81	₹54.16	₹32.90
	₹64.00	₹60.34	₹59.81	₹54.16	₹32.90
Other comprehensive income — detail
	1,512	1,965	304	—	—
	5.9	10.9	−8.4	−13.6	1.4
	3.0	2.7	−2.1	—	—
	—	—	—	−3.0	2.0
	1,510	1,957	310	110	736
	5,225	5,470	3,790	3,272	2,663
	−1.8	−1.8	−2.3	−4.0	0.2
Per share — as-filed variants
	₹64.00	₹60.34	₹59.81	₹54.16	₹32.90
	₹64.00	₹60.34	₹59.81	₹54.16	₹32.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	21,059	20,165	18,697	16,399	13,562
	60.3%	59.9%	58.9%	56.5%	54.6%
Adjusted (ex-exceptional items) — derived
	5,528	5,176	5,098	4,589	2,624
	−106	−65.3	0.0	−192	0.0
	3,783	3,548	3,484	3,308	1,928
	₹65.25	₹61.11	₹59.81	₹56.54	₹32.90

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹95,530 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	24,855.4	29,001.9	31,723.7	33,653.1	34,935.3
Other Income	290.6	557.4	621.9	492.1	689.5
Total Income	25,146.0	29,559.3	32,345.6	34,145.2	35,624.8
Expenses
+ Cost of Materials Consumed	9,652.5	10,776.1	10,736.8	10,305.2	10,664.4
+ Purchases of Stock-in-Trade	2,050.4	2,772.9	2,887.1	3,478.0	3,602.0
+ Changes in Inventories	-409.7	-946.2	-597.6	-294.8	-390.3
+ Employee Benefit Expense	3,522.3	3,922.9	4,475.6	5,190.2	5,441.5
+ Finance Costs	140.5	289.7	457.2	384.0	387.9
+ Depreciation & Amortisation	1,244.6	1,521.7	1,649.4	1,778.2	1,859.3
+ Other Expenses	6,321.2	6,633.0	7,639.1	8,128.8	8,532.4
Total Expenses	22,521.8	24,970.2	27,247.6	28,969.5	30,097.2
EBITDA	3,718.6	5,843.0	6,582.8	6,845.7	7,085.3
EBIT	2,474.1	4,321.3	4,933.4	5,067.5	5,226.0
Profit
PBT before Exceptional Items	2,624.2	4,589.0	5,098.0	5,175.7	5,527.6
+ Exceptional Items	0.0	-191.9	0.0	-65.3	-105.5
Pretax Income	2,624.2	4,397.2	5,098.0	5,110.3	5,422.1
+ Current Tax	1,071.5	1,777.5	1,700.0	1,736.1	1,855.4
+ Deferred Tax	-386.6	-566.5	-117.3	-127.3	-146.1
Tax Expense	684.9	1,211.0	1,582.7	1,608.9	1,709.3
+ Share of Associates & JVs	-11.7	-17.2	-31.7	1.5	-1.9
Net Income	1,927.7	3,169.0	3,483.6	3,503.0	3,710.8
+ Net Income — Continuing Ops	1,939.3	3,186.1	3,515.3	3,501.5	3,712.7
+ Other Comprehensive Income	735.6	99.2	303.6	1,965.2	1,512.5
Total Comprehensive Income	2,663.2	3,268.1	3,787.2	5,468.2	5,223.3
Net Income to Common	1,927.5	3,173.0	3,485.9	3,504.8	3,712.6
Minority Interest	0.2	-4.0	-2.3	-1.8	-1.8
Per Share
Basic EPS	32.90	54.16	59.81	60.34	64.00
Diluted EPS	32.90	54.16	59.81	60.34	64.00
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	303.6	1,965.2	1,512.5
+ Items NOT to be Reclassified to P&L	1.4	-13.6	-8.4	10.9	5.9
+ Tax on Items NOT to be Reclassified	—	—	-2.1	2.7	3.0
+ Tax on Items NOT to be Reclassified — alt tag	2.0	-3.0	—	—	—
+ Items to be Reclassified to P&L	736.2	109.9	309.9	1,957.0	1,509.6
Comprehensive Income — Owners of Parent	2,663.1	3,272.1	3,789.5	5,469.9	5,225.0
Comprehensive Income — Non-controlling Interests	0.2	-4.0	-2.3	-1.8	-1.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	32.90	54.16	59.81	60.34	64.00
Diluted EPS — Continuing Operations	32.90	54.16	59.81	60.34	64.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	13,562.1	16,399.0	18,697.5	20,164.7	21,059.2
Gross Margin %	54.56	56.54	58.94	59.92	60.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	2,624.2	4,589.0	5,098.0	5,175.7	5,527.6
− Exceptional Items (reconciliation)	0.0	-191.9	0.0	-65.3	-105.5
Net Income Adj (tax-effected)	1,927.7	3,308.0	3,483.6	3,547.7	3,783.0
EPS Adj	32.90	56.54	59.81	61.11	65.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	58.6	58.6	58.1	58.1	57.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.